It’s time for some fun.
Over the past 20 years or so, I’ve made it my mission to hunt down some of the most promising private biotechs in the industry to feature in an annual report I now call the Endpoints 11. And we’re back on track for the next big round of awards.
Every now and then I’m asked what the basic criteria is for inclusion. It’s simple. If you’re out to do big things in drug development, break new ground, go to that proverbial next level with an outstanding team, promising science and marquee backers — or promise to make a colossal noise if you fail — then you should make the short list.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.